•  
  •  
  •  
  •  

2025-10-01 01:56:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores

Keywords Selected:  INE540L01014

Stock Report

  • Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer
  • Alkem launches Olesoft Trucera, an advanced ceramide-boosting moisturizing lotion for skin barrier repair
  • Alkem Medtech to acquire 100% stake of Bombay Ortho
  • US FDA Inspection at Alkem Laboratories Ltd's Bioequivalence Center located at Taloja
  • Alkem Laboratories launches generic empagliflozin and its combinations in India under the brand name 'Empanorm'
  • Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics
  • Alkem Laboratories denies claims of Pan-D, Clavam 625 batches being not-of-standard quality
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Baddi, India
  • Alkem Laboratories Ltd receives Form 483 with 10 observations for Baddi facility
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's API manufacturing facility located at Mandva
  • Alkem Laboratories Ltd updates on sale of S&B Pharma LLC's facility
  • Alkem Laboratories Ltd receives 3 observations from USFDA for API manufacturing facility located at Mandva
  • BIOSERGEN, ALKEM collaborate to develop anti-infective for severe fungal infections
  • Alkem Laboratories Ltd recommends final dividend of Rs. 10
  • Closure of US FDA Inspection at Alkem's manufacturing facility located at Indore
  • Alkem Laboratories Ltd declares special dividend of Rs. 25
  • US FDA Inspection at Alkem's manufacturing facility located at Indore
  • US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA
  • MHRA Inspection at Alkem's Bioequivalence Center at Taloja
  • Alkem Laboratories Ltd board recommends final dividend of Rs. 4
  • US FDA Inspection at Alkem's Bioequivalence Center at Taloja
  • ISP Chile Inspection at Alkem's manufacturing facility located at Baddi, India
  • ISP Chile inspects at Alkem's manufacturing facility located at Daman, India
  • ALKEM licenses technology from Harvard University, aiming to treat ischemic injurv and vascular diseases

Latest Post

  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024